| Schedule of Financial Data for the Company’s Reportable Segment |
The
following table presents specific financial data for the Company’s reportable segment (in thousands):
Schedule
of Financial Data for the Company’s Reportable Segment
| (Dollar amounts in thousands) | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| | |
Three months ended June 30, | | |
Six months ended June 30, | |
| (Dollar amounts in thousands) | |
2026 | | |
2025 | | |
2026 | | |
2025 | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| Research & development expenses-clinical asset development | |
$ | 185 | | |
$ | 222 | | |
$ | 447 | | |
$ | 411 | |
| Research & development expense – related parties | |
| 117 | | |
| 1,638 | | |
| 633 | | |
| 2,365 | |
| Research & development expense | |
| 117 | | |
| 1,638 | | |
| 633 | | |
| 2,365 | |
| | |
| | | |
| | | |
| | | |
| | |
| General and administrative expenses – legal & professional fees | |
| 300 | | |
| 872 | | |
| 1,013 | | |
| 1,632 | |
| General and administrative expenses – accounting & audit fees | |
| 639 | | |
| 378 | | |
| 1,348 | | |
| 922 | |
| General and administrative expenses – salaries, payroll and stock based compensation | |
| 470 | | |
| 751 | | |
| 1,013 | | |
| 1,444 | |
| General and administrative expenses - other | |
| 1,291 | | |
| 1,091 | | |
| 2,204 | | |
| 1,794 | |
| General and administrative expenses | |
| 1,291 | | |
| 1,091 | | |
| 2,204 | | |
| 1,794 | |
| Total operating costs and expenses | |
| 3,002 | | |
| 4,952 | | |
| 6,658 | | |
| 8,568 | |
| Operating loss | |
| (3,002 | ) | |
| (4,952 | ) | |
| (6,658 | ) | |
| (8,568 | ) |
| Other income (expenses): | |
| | | |
| | | |
| | | |
| | |
| Other expense | |
| (1,536 | ) | |
| (1,023 | ) | |
| (1,826 | ) | |
| (1,992 | ) |
| Loss on investment | |
| (86 | ) | |
| - | | |
| (154 | ) | |
| - | |
| Interest income | |
| - | | |
| 4 | | |
| - | | |
| 12 | |
| Interest expense, net | |
| (17 | ) | |
| (57 | ) | |
| (66 | ) | |
| (233 | ) |
| Total other (expense) income, net | |
| (1,639 | ) | |
| (1,076 | ) | |
| (2,046 | ) | |
| (2,213 | ) |
| Net loss | |
$ | (4,641 | ) | |
$ | (6,028 | ) | |
$ | (8,704 | ) | |
$ | (10,781 | ) |
|
The
following table presents certain financial data for the Company’s reportable segment (in thousands):
Schedule
of Financial Data for the Company’s Reportable Segment
| (Dollar amounts
in thousands) | |
2025 | | |
2024 | |
| | |
December
31, | |
| (Dollar amounts
in thousands) | |
2025 | | |
2024 | |
| Operating expenses: | |
| | | |
| | |
| Research & development expenses-clinical
asset development | |
$ | 802 | | |
$ | 3,278 | |
| Research & development expense –
related parties | |
| 3,952 | | |
| 100 | |
| Research & development expense –
related parties - digital assets | |
| 300 | | |
| - | |
| General and administrative expenses –
legal & professional fees | |
| 4,682 | | |
| 2,258 | |
| General and administrative expenses – litigation liability accrual | |
| 9,594 | | |
| - | |
| General and administrative expenses –
accounting & audit fees | |
| 1,749 | | |
| 1,625 | |
| General and administrative expenses –
salaries, payroll and stock-based compensation | |
| 5,020 | | |
| 4,098 | |
| General and administrative expenses - issuance of common stock and pre-funded warrants | |
| 7,000 | | |
| - | |
| General and administrative
expenses - other | |
| 3,658 | | |
| 4,060 | |
| General and administrative
expenses | |
| 3,658 | | |
| 4,060 | |
| Total
operating costs and expenses | |
| 36,757 | | |
| 15,419 | |
| Operating loss | |
| (36,757 | ) | |
| (15,419 | ) |
| Other expenses: | |
| | | |
| | |
| Other expense | |
| (1,774 | ) | |
| (890 | ) |
| Other expense – digital assets | |
| (402 | ) | |
| - | |
| Total other expense, net | |
| (2,176 | ) | |
| (890 | ) |
| Interest Income | |
| 28 | | |
| 13 | |
| Interest expense, net | |
| (319 | ) | |
| (1,506 | ) |
| Total
other expense, net | |
| (2,467 | ) | |
| (2,383 | ) |
| Net
loss | |
$ | (39,224 | ) | |
$ | (17,802 | ) |
|